Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study ; day:20 ; month:8 ; year:2022 ; pages:1-7
Drugs in R & D ; (20.8.2022), 1-7
- Creator
-
Umemiya, Maki
Inayama, Yoshihide
Nakatani, Eiji
Ito, Kenta
Tsuji, Mitsuru
Yoshida, Teruki
Yu, Sae
Gou, Rei
Horikawa, Naoki
Tani, Hirohiko
Kosaka, Kenzo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-022-00399-y
- URN
-
urn:nbn:de:101:1-2022110921101706293690
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2024, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Umemiya, Maki
- Inayama, Yoshihide
- Nakatani, Eiji
- Ito, Kenta
- Tsuji, Mitsuru
- Yoshida, Teruki
- Yu, Sae
- Gou, Rei
- Horikawa, Naoki
- Tani, Hirohiko
- Kosaka, Kenzo
- SpringerLink (Online service)
Other Objects (12)
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Mesostructured silica matrix for irinotecan delivery systems
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
Mesostructured silica matrix for irinotecan delivery systems
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
High‐Load CoreShell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan